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Introduction
HF occurs when the heart is unable to deliver 
blood and oxygen at a rate that meets the 
requirements of the body. It is characterised 
by symptoms of breathlessness, fatigue 
upon exertion, and signs of fluid retention. 
Some people with HF have left ventricular 
systolic dysfunction (LVSD), with reduced 
left ventricular ejection fraction, typically 
identified on echocardiography. Others have 
HF with a preserved ejection fraction. Most 
of the evidence relating to drug treatment 
is for HF due to LVSD.1 Two classifications of 
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Educational aims
•	 To	provide	an	update	of	the	most	recent	guideline	recommendations	for	the	
pharmacotherapeutic management of heart failure.
•	 To	distinguish	between	those	drugs	which	offer	symptomatic	relief	and	those	which	
offer prognostic benefit.
•	 To	highlight	the	monitoring	requirements	associated	with	the	drugs	used.
the severity of HF are commonly employed 
(Figure 1). The New York Heart Association 
(NYHA) functional classification is based 
on symptoms and exercise capacity and is 
employed routinely in most randomized 
clinical trials.2 The American College of 
Cardiology/American Heart Association (ACC/
AHA) classification describes HF in stages 
based on structural changes and symptoms.3 
The most common cause of HF is 
coronary artery disease, which accounts 
for around 70% of cases.4 Other causes 
are hypertension, valvular disease, and 
arrhythmias such as atrial fibrillation. 
Advancing age, smoking, hyperlipidaemia and 
diabetes mellitus are among the associated 
risk factors. Infections, anaemia, alcohol 
abuse, side effects of medication such as 
non-steroidal anti-inflammatory drugs, and 
non-compliance with prescribed treatment can 
also exacerbate HF.5 
In Europe, the prevalence of HF is between 
2 and 3% and rises sharply at around 75 years 
of age; the prevalence in seventy to eighty 
year-old people is between 10 and 20%. 
In younger age groups HF is more common 
in men because the most common cause, 
coronary heart disease, occurs in earlier 
decades. In the elderly, the prevalence is equal 
between the sexes.5 The overall prevalence 
of HF is increasing because of ageing of the 
population, improved survival of patients with 
coronary artery disease and more effective 
treatments for HF.6
Drug treatment strategy
Patients with HF have a shorter life expectancy 
and experience symptoms that can reduce 
their quality of life. The aims of treatment are 
to reduce the risk of mortality, delay disease 
progression, control symptoms and improve 
quality of life. 
Over the past two decades, the therapeutic 
approach to HF patients has undergone 
considerable change. Several drug classes have 
been introduced targeting the two biological 
pathways implicated in progression of the 
disease, the renin-angiotensin-aldosterone 
system and the sympathetic nervous 
system. Current treatment not only concerns 
symptomatic improvement, but increasingly 
focuses on delaying disease progression and 
on reducing mortality. 
Angiotensin-converting enzyme inhibitors
There is evidence to support the use of 
angiotensin-converting enzyme inhibitors 
(ACEIs) in all patients with LVSD. ACEIs 
improve symptoms, reduce hospitalisation 
rate, and improve survival rate.7,8,9,10,11 ACEIs 
should be offered to all patients with HF due 
to LVSD (Figure 2).1
ACEIs should be started at a low dose and 
titrated upwards at short intervals of at least 
two weeks until the optimal tolerated or target 
dose is achieved. The safety of treatment with 
ACEIs is best achieved by monitoring serum 
potassium, urea, creatinine and estimated 
glomerular filtration rate (eGFR) before the 
initiation of ACEIs, one to two weeks following 
each dose increment, and then every three 
to six-months thereafter.1,5 Hyperkalaemia is 
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a potential problem during therapy. Mildly 
raised potassium levels (5.0-6.0mmol/L) can 
often be managed by dietary modifications 
(foods containing high levels of potassium 
e.g. banana, tomatoes and citrus fruits to be 
avoided). Cessation of treatment should only 
be considered if serum potassium is more 
than 6mmol/L.1,5 An increase in creatinine is 
expected when an ACEI is initiated, but the 
action taken should be determined by the 
extent of the rise. According to guidelines 
from the European Society of Cardiology, 
an increase in creatinine of up to 50% from 
baseline or to an absolute concentration 
of 265µmol/L, whichever is lower, is 
acceptable. If the creatinine rises above 
265µmol/L, but below 310µmol/L, the dose 
of ACEI should be halved. If the creatinine 
rises to 310µmol/L or above, the ACEI should 
be stopped immediately.5 According to NICE 
guidelines, a change in creatinine of less 
than 30% or in eGFR of less than 25% is 
acceptable; if the change is greater, the ACEI 
should be stopped or the dose reduced to a 
previously tolerated lower dose.1
Cough is a common adverse effect of 
ACEIs and switching to an angiotensin 
receptor blocker is recommended.5 
Symptomatic hypotension (e.g. dizziness) is 
also common but often improves with time, 
and patients should be reassured. Reducing 
the dose of diuretics and other hypotensive 
agents should be considered. Asymptomatic 
hypotension does not require intervention.5
Angiotensin receptor blockers
There is significant evidence supporting to 
use of angiotensin receptor blockers (ARBs) 
in the management of HF, although this 
is weaker than that for ACEIs.12,13,14,15,16,17 
Unlike ACEIs they do not cause dry cough, 
one of the most common causes of stopping 
ACEI therapy. When patients are intolerant 
of ACEIs, the introduction of ARBs is 
proposed as an alternative.1 ARBs are also 
recommended as second-line treatment if a 
patient remains symptomatic despite optimal 
therapy with an ACEI and a BB, especially if 
the patient has mild to moderate HF (NYHA 
class II-III) (figure 2).1 Monitoring of serum 
potassium, urea, creatinine and eGFR for 
signs of hyperkalaemia or renal impairment is 
recommended as for ACEIs.
Beta blockers
Patients who have HF with LVSD should 
be considered for the introduction of BBs. 
In these patients BBs have been shown 
to reduce morbidity, hospitalisation and 
mortality. BBs of proven efficacy in HF 
include carvedilol, nebivolol, bisoprolol 
and metoprolol succinate.18,19,20,21,22,23,24 
According to the recent NICE guidelines 
(figure 2), both ACEIs and BBs licensed for 
HF should be offered to all patients with 
HF due to LVSD, using clinical judgement 
when deciding which drug to start first.1 This 
recommendation resulted from evidence from 
the CIBIS III trial indicating that HF patients 
derived similar outcome of therapy with 
ACEIs followed by BBs, to those treated with 
BBs followed by ACEIs.25 The clinical decision 
to use one of these two agents before the 
other depends on the clinical status of the 
patient. Several factors could affect the 
choice, including blood pressure, heart rate 
as well as the presence of symptomatic 
ischaemia, arrhythmias and other co-
morbidities.1 
BBs should not be withheld from older 
adults and patients with peripheral vascular 
disease (unless severe), erectile dysfunction, 
diabetes mellitus, interstitial pulmonary 
disease and chronic obstructive pulmonary 
disease without reversibility. Stable patients 
who are already taking a BB for a concurrent 
disease (e.g. angina or hypertension) and 
who develop HF due to LVSD, should be 
switched to a BB licensed for HF.1
Treatment should be started in stable 
patients at low doses and up-titrated slowly 
at intervals of at least two to four weeks. It 
is important, during the up-titration of BBs, 
to monitor the patient’s pulse rate, blood 
pressure and the clinical status, to avoid side 
effects such as symptomatic bradycardia and 
symptomatic hypotension. The up-titration 
should be undertaken gradually and slowly 
to achieve the target doses used in the 
clinical trials, if tolerated. The patient needs 
to be informed that transient pulmonary 
congestion could occur at times during up-
titration of BBs.1,5
Aldosterone antagonists
There is evidence of enhanced activity of 
the renin-angiotensin-aldosterone system 
in patients with HF. The modulation of 
this system started with the introduction 
of ACEIs, and followed by the introduction 
of the ARBs in the treatment of HF. 
Spironolactone, an aldosterone antagonist 
(AA), was contra-indicated in combination 
with ACEIs, until the publication of the 
RALES study in 1999.26 Evidence from this 
study indicated that moderately to severely 
symptomatic patients with HF (NYHA class 
III-IV), despite optimal medical therapy, 
attained lower hospitalisation rates and 
higher survival rates with the addition 
of spironolactone. A more recent trial 
investigating the newer AA, eplerenone, in 
patients with LVSD and clinical evidence of 
HF or diabetes mellitus within 14 days of 
a myocardial infarction (MI) also showed 
prognostic benefit in these patients.27 In fact 
ACC/AHA stages of heart failure NYHA functional classification
Stage of heart failure based on structure and damage to heart muscle Severity based on symptoms and physical activity
Stage A
At high risk for developing heart failure. No identified structural  
or functional abnormality; no signs or symptoms. Class I
No limitation of physical activity. Ordinary physical activity does 
not cause undue fatigue, palpitation, or dyspnoea.
Stage B
Developed structural heart disease that is strongly associated with 
the development of heart failure, but without signs or symptoms. Class II
Slight limitation of physical activity. Comfortable at rest, but 
ordinary physical activity results in fatigue, palpitation, or 
dyspnoea.
Stage C
Symptomatic heart failure associated with underlying structural 
heart disease. Class III
Marked limitation of physical activity. Comfortable at rest, but less 
than ordinary activity results in fatigue, palpitation, or dyspnoea.
Stage D
Advanced structural heart disease and marked symptoms of heart 
failure at rest despite maximal medical therapy. Class IV
Unable to carry on any physical activity without discomfort. 
Symptoms at rest. If any physical activity is undertaken, discomfort 
is increased.
ACC American College of Cardiology; AHA American Heart Association; NYHA New York Heart Association
Figure 1: Classification of heart failure by structural abnormality (ACC/AHA), or by symptoms relating to functional capacity (NYHA)
Figure 2: NICE algorithm for the treatment of heart failure (HF)1
HF
HF with preserved 
ejection fraction
HF due to left 
ventricular systolic 
dysfunction
Manage comorbid conditions 
such as high blood pressure, 
ischaemic heart disease and 
diabetes mellitus in line with 
NICE guidance
If symptoms persist despite optimal first-
line treatment, seek specialist advice and for 
second-line treatment consider adding:  
•	 an	AA	licensed	for	HF	(especially	in	moderate	
to severe HF/MI in past month) or
•	 an	ARB	licensed	for	HF	(especially	in	mild	to	
moderate HF) or
•	 hydralazine	in	combination	with	nitrate	
(especially in people of African or Caribbean 
origin with moderate to severe HF)
Offer both ACEIs and BBs licensed 
for HF as first-line treatment
If sysmptoms persist:
•	 CRT	(pacing	with	or	without	a	defibrillator)
•	 digoxin
Consider an ARB 
if intolerant of ACEIs
Consider hydralazine in 
combination with nitrate if 
intolerant of ACEIs and ARBs
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ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta-blocker, AA aldosterone antagonist,  
MI myocardial infarction, ICD implantable cardiovascular defibrillator, CRT cardiac resynchronisation therapy
ACEI enalapril 2.5mg once daily to 10-20mg twice daily
 lisinopril 2.5mg once daily to 35mg once daily
 perindopril arginine 2.5mg once daily to 5mg once daily
ARB candesartan 4mg once daily to 32mg once daily
 losartan 12.5mg once daily to 50mg once daily 
valsartan 40mg twice daily to 160mg twice daily
BB carvedilol 3.125mg twice daily to 25-50mg twice daily
 nebivolol 1.25mg once daily to 10mg once daily
 
AA spironolactone 12.5-25mg once daily to 50mg once daily
hydralazine 25mg three to four times daily to 50-75mg four times 
daily
isosorbide dinitrate 20mg three times daily to 40mg three times 
daily
digoxin 62.5-125mcg once daily, up to 250mcg daily in atrial 
fibrillation
Initial and target doses of selected agents used in the treatment of HF5,29
lower doses may be required in elderly and in renal or liver impairment
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NICE guidelines (Figure 2) recommend that 
an AA should be considered as second-line 
treatment if a patient remains symptomatic 
despite optimal therapy with an ACEI and 
a BB especially if the patient has moderate 
to severe HF (NYHA class III–IV) or has had 
an MI within the past month. For patients 
who have had an acute MI and who have 
symptoms and/or signs of HF and LVSD, 
treatment with an AA licensed for post-MI 
treatment should be initiated within 3 to 
14 days of the MI, preferably after ACEI 
therapy.1 From a health economic point 
of view, the substantially lower cost of 
spironolactone compared to eplerenone 
suggests that spironolactone should be 
used in moderate to severe chronic HF, and 
eplerenone should be used in the patients 
with HF following MI.1 
Treatment should be initiated at a low 
dose and up-titration considered only after 
four to eight weeks. Hyperkalaemia and a 
decline in renal function are common among 
patients prescribed AAs. Monitoring of 
serum potassium, urea, creatinine and eGFR 
is recommended at one, two, three and six 
months and six-monthly thereafter. The dose 
of AA should be halved if the potassium 
level rises to 5.5-5.9mmol/L and stopped 
immediately if potassium is above 6mmol/L. 
Similarly the dose should be halved if 
the creatinine level rises to below 220 
µmol/L and stopped if creatinine is above 
220µmol/L.1,5
Diuretics
The use of diuretics in the treatment of 
HF is well established and essential for 
symptomatic relief when fluid overload 
is present. However, there is no evidence 
that loop and thiazide diuretics improve 
the prognosis of patients with HF. 
Diuretics should be titrated (up and down) 
according to need following the initiation 
of subsequent HF therapies. Monitoring of 
serum sodium, potassium, creatinine and 
eGFR should be carried out particularly in 
the acute stage when doses are increased. 
Care must be taken not to leave patients on 
unnecessarily high doses of diuretics; the 
dose should be decreased to the minimum 
required for symptom control.1,5
Hydralazine plus nitrate
Evidence for the combination of hydralazine 
and nitrate comes from the AHEFT study 
in which the addition of the combination 
to optimal therapy (ACEI, BB and AA) in 
black patients with moderate to severe HF 
(mainly NYHA class III) reduced morbidity 
and mortality.28 Black patients of African 
and Caribbean descent have been found to 
derive less benefit than non-blacks from 
ACEIs in both HF and hypertension trials, 
and it is this group to which this evidence is 
applicable.
NICE guidelines (Figure 2) recommend 
that hydralazine in combination with nitrate 
be considered for patients with HF due to 
LVSD who are intolerant of ACEIs and ARBs. 
As second-line treatment the combination 
is to be considered if a patient remains 
symptomatic despite optimal therapy with an 
ACEI and a BB, especially if the patient is of 
African or Caribbean origin and has moderate 
to severe HF (NYHA class III-IV).1 
Hypotension is a potential adverse effect 
with this drug combination although it 
often improves with time. If symptomatic, 
reducing the doses of other hypotensive 
agents (except ACEI/ARB/BB/AA) should be 
considered. Lupus-like syndrome due to the 
hydralazine component should be considered 
in the case of symptoms of arthralgia/muscle 
aches, joint pain or swelling, pericarditis, 
rash or fever.5
Digoxin
Digoxin is one of the oldest known 
treatments for HF. Although it has an 
established role as a rate controller in 
patients with concomitant atrial fibrillation, 
its indication in HF patients in sinus rhythm 
is limited. According to NICE guidelines, 
digoxin is recommended for worsening or 
severe HF due to LVSD despite first- and 
second-line treatment for HF (Figure 2).1 
Digoxin is well known for its potential 
for toxicity. Unwanted effects depend upon 
the concentration of the cardiac glycoside 
in the plasma and on the sensitivity of the 
conducting system or of the myocardium.29 
Regular monitoring of plasma digoxin 
concentration during maintenance 
treatment is not necessary but is indicated 
for initiation of treatment, confirmation 
or exclusion of toxicity, impaired renal 
function, co-administration of drugs which 
affect digoxin levels or to confirm patient 
compliance with the drug.5,30 If an assay 
is indicated, blood should be sampled for 
digoxin at least six hours after an oral dose 
is administered. Samples should be taken at 
least eight days after initiation or change in 
dose. Sampling times should be recorded if 
assay results are to be interpreted correctly. 
The serum digoxin concentration should be 
interpreted in the clinical context as toxicity 
may occur even when the concentration is 
within the ‘therapeutic range’. Various clinical 
factors predispose patients to digoxin 
toxicity. Hypokalaemia, hypercalcaemia and 
hypomagnesaemia all lead to an increase 
in responsiveness of cardiac tissues to 
the effects of digoxin. Correction of these 
underlying factors is therefore an important 
part of management.30 
Conclusion
Managing HF is a challenge and evidence-
based guidelines should be utilised so as 
to provide optimal treatment and improve 
patient outcomes. Regular review including 
monitoring of both laboratory and clinical 
parameters is essential for safe and effective 
management.
•	 ACEIs	and	ARBs	should	be	started	at	a	low	dose	and	titrated	upwards	at	short	
intervals of at least two weeks until the optimal tolerated or target dose is achieved. 
Monitor potassium, urea, creatinine, eGFR and blood pressure.
•	 BBs	should	only	be	initiated	or	titrated	upwards	when	the	patient	is	clinically	stable.
•	 BBs	should	be	started	at	a	low	dose	and	titrated	upwards	gradually	at	intervals	of	
at least two to four weeks until the optimal tolerated or target dose is achieved. 
Monitor blood pressure, pulse rate and for signs of worsening HF.
•	 AAs	should	be	started	at	a	low	dose	and	titrated	upwards	after	four	to	eight	weeks	
until the optimal tolerated or target dose is achieved. Monitor potassium, urea, 
creatinine and eGFR.
•	 After	an	exacerbation,	the	dose	of	diuretic	should	be	titrated	downwards	to	the	
minimal dose necessary to maintain the patient in a fluid-free state. Monitor 
electrolytes, uric acid, urea, creatinine, eGFR, fluid status and blood pressure.
•	 Patients	on	digoxin	should	be	monitored	for	factors	which	enhance	the	risk	for	
toxicity.
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